Dabigatran (pradaxa) manufacturing plant cost?

I don’t have a single reliable public figure for the total “manufacturing plant cost” specifically for dabigatran (Pradaxa)—that kind of exact capex is usually reported only for particular projects (and often in ranges) and may be company-confidential.

What I can do is help you estimate or find the right number depending on what you mean:

1) Which “plant cost” do you mean?

• A new API/bulk drug substance facility (dabigatran active ingredient)
• A formulation/finished-dose facility (capsules/packaging)
• A specific expansion or compliance upgrade (GMP, capacity add, solvent handling, etc.)
• Any facility used by the manufacturer(s) (Boehringer Ingelheim for Pradaxa in general)

2) Where costs are often disclosed (if you’re doing research)

For pharma, costs sometimes appear in:

• Annual reports / investor presentations (capex by project)
• GMP site announcements (commissioning dates, capacity expansions)
• Regulatory filings (less often $ amounts, more often scope)
• News coverage tied to a specific site expansion (may mention “tens/hundreds of millions”)

3) Quick path to get you an accurate figure

If you tell me:

1. Manufacturer (e.g., Boehringer Ingelheim) and/or country/site you care about
2. Whether you want API or finished-dose production
3. Timeframe (e.g., last decade? which expansion?)

…I can help you locate the most relevant publicly reported cost (or provide a defensible estimate range).

Question: Do you mean the cost for a specific dabigatran manufacturing site (which location?), or are you asking for a general estimate of what it costs to build a GMP plant that could make dabigatran?